Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1940360 | 0.90 | WHR1 (0.55) | WHR1PDGFRBPDGFRAADORA2ATP53 | |
| SCHEMBL1941112 | 0.86 | WHR1 (0.60) | WHR1PDGFRBPDGFRAALDH1A1KDM4E | |
| SCHEMBL27117037 | 0.86 | WHR1 (0.71) | WHR1PDGFRBPDGFRAALDH1A1KDM4E | |
| SCHEMBL27777423 | 0.86 | EGFR (0.47) | WHR1PDGFRBPDGFRAADORA2AALDH1A1 | |
| SCHEMBL295421 | 0.85 | WHR1 (0.52) | WHR1ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL1941684 | 0.85 | WHR1 (0.52) | WHR1ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL1941739 | 0.85 | PDGFRB (0.50) | WHR1PDGFRBPDGFRAADORA2ATP53 | |
| SCHEMBL1942183 | 0.82 | WHR1 (0.49) | WHR1ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL26565406 | 0.82 | PRNP (0.56) | ADORA2ATP53ALDH1A1KDM4ELMNA | |
| SCHEMBL27782140 | 0.81 | RAF1 (0.43) | WHR1PDGFRAPDE4APDE4DEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | NSUN2, RNMT, TRDMT1 | WHR1 753/4885PDGFRB 4564/4885PDGFRA 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.